To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Clinical outcome of patie… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Clinical outcome of patients with brain metastases from breast cancer - A population based study over 21 years.

Journal article
Authors Anna Thulin
Elisabeth Werner Rönnerman
Chenyang Zhang
Shahin De Lara
Chaido Chamalidou
Arnd Schoenfeldt
Carola Andersson
Anikó Kovács
Fredrik Enlund
Barbro Linderholm
Published in Breast
Volume 50
Pages 113-124
ISSN 1532-3080
Publication year 2020
Published at Institute of Clinical Sciences, Department of Oncology
Pages 113-124
Language en
Links dx.doi.org/10.1016/j.breast.2020.02...
www.ncbi.nlm.nih.gov/entrez/query.f...
Keywords oncology, breast cancer
Subject categories Cancer and Oncology

Abstract

Brain metastases (BM) are a feared progression of breast cancer (BC) with impact on quality of life and survival. Despite improved treatments, it is believed patients suffering from BM are increasing.To study potential changes in the number of BM, the possible links between BC subgroup and extent of BM with prognosis. To investigate the interval between primary BC/extra cranial recurrence, and diagnosis of BM in the years 1994-2014.Clinical data from 191 patients with BM diagnosed 1994-2014, was retrieved from charts. Primary tumours where re-evaluated histologically.There was an increase of BM in 5 years cohorts (1994-99 (n = 9); 2000-04 (n = 36); 2005-09 (n = 60); 2010-14 (n = 86)). We found no difference in the time interval from primary BC to BM but an insignificant increase in time from extra cranial relapse to development of BM in the time periods 1994-2004 and 2005-2014 of 15.5 and 25.0 months (p = 0.0612). Survival after BM was 7 months (95% CI 6-10) with a statistically significant difference between HER2 positive and TNBC with an inferior outcome for the latter (p = 0.018) whilst no differences were present when Luminal BC were compared with HER2 positive BC (p = 0.073).We show an increase of BM over time whilst the time span from primary BC to BM is unchanged supports earlier findings that adjuvant treatments have little preventive function. Time from extra cranial recurrence to BM was prolonged with one year. Patients with TNBC or more advance extent of BM had the shortest survival with BM.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?